Status:
TERMINATED
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
Lead Sponsor:
Sun Pharmaceutical Industries, Inc.
Conditions:
Lice Infestations
Eligibility:
All Genders
6-24 years
Phase:
PHASE2
Brief Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation ...
Eligibility Criteria
Inclusion
- Confirmed active head lice infestation
- Parent or guardian must be able to apply treatment
Exclusion
- Allergy to pediculicides or hair care products
- Scalp conditions other than head lice
- Previous head lice treatment within the past 4 weeks
- Current antibiotic treatment
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00291057
Start Date
February 1 2006
End Date
December 1 2006
Last Update
December 23 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigator Site
Scottsdale, Arizona, United States
2
Investigator Site
St. Petersburg, Florida, United States
3
Investigator Site
West Palm Beach, Florida, United States
4
Investigator Site
New York, New York, United States